These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
166 related articles for article (PubMed ID: 37686138)
41. Metabolic signatures across the full spectrum of non-alcoholic fatty liver disease. McGlinchey AJ; Govaere O; Geng D; Ratziu V; Allison M; Bousier J; Petta S; de Oliviera C; Bugianesi E; Schattenberg JM; Daly AK; Hyötyläinen T; Anstee QM; Orešič M JHEP Rep; 2022 May; 4(5):100477. PubMed ID: 35434590 [TBL] [Abstract][Full Text] [Related]
42. Type 2 diabetes mellitus is associated with the fibrosis severity in patients with nonalcoholic fatty liver disease in a large retrospective cohort of Japanese patients. Nakahara T; Hyogo H; Yoneda M; Sumida Y; Eguchi Y; Fujii H; Ono M; Kawaguchi T; Imajo K; Aikata H; Tanaka S; Kanemasa K; Fujimoto K; Anzai K; Saibara T; Sata M; Nakajima A; Itoh Y; Chayama K; Okanoue T; J Gastroenterol; 2014 Nov; 49(11):1477-84. PubMed ID: 24277052 [TBL] [Abstract][Full Text] [Related]
43. Plasma Fibroblast Growth Factor 21 Is Associated With Severity of Nonalcoholic Steatohepatitis in Patients With Obesity and Type 2 Diabetes. Barb D; Bril F; Kalavalapalli S; Cusi K J Clin Endocrinol Metab; 2019 Aug; 104(8):3327-3336. PubMed ID: 30848827 [TBL] [Abstract][Full Text] [Related]
44. Histological severity of nonalcoholic fatty liver disease is associated with 10-year risk for atherosclerotic cardiovascular disease. Park JH; Koo BK; Kim W; Kim WH; Hepatol Int; 2021 Oct; 15(5):1148-1159. PubMed ID: 34081289 [TBL] [Abstract][Full Text] [Related]
45. ADAMTSL2 protein and a soluble biomarker signature identify at-risk non-alcoholic steatohepatitis and fibrosis in adults with NAFLD. Corey KE; Pitts R; Lai M; Loureiro J; Masia R; Osganian SA; Gustafson JL; Hutter MM; Gee DW; Meireles OR; Witkowski ER; Richards SM; Jacob J; Finkel N; Ngo D; Wang TJ; Gerszten RE; Ukomadu C; Jennings LL J Hepatol; 2022 Jan; 76(1):25-33. PubMed ID: 34600973 [TBL] [Abstract][Full Text] [Related]
46. Increased Body Mass Index and Type 2 Diabetes Are the Main Predictors of Nonalcoholic Fatty Liver Disease and Advanced Fibrosis in Liver Biopsies of Patients With Human Immunodeficiency Virus Monoinfection. Maurice JB; Goldin R; Hall A; Price JC; Sebastiani G; Morse CG; Prat LI; Perazzo H; Garvey L; Ingiliz P; Guaraldi G; Tsochatzis E; Lemoine M Clin Infect Dis; 2021 Oct; 73(7):e2184-e2193. PubMed ID: 32877569 [TBL] [Abstract][Full Text] [Related]
47. Prospective evaluation of the prevalence of non-alcoholic fatty liver disease and steatohepatitis in a large middle-aged US cohort. Harrison SA; Gawrieh S; Roberts K; Lisanti CJ; Schwope RB; Cebe KM; Paradis V; Bedossa P; Aldridge Whitehead JM; Labourdette A; Miette V; Neubauer S; Fournier C; Paredes AH; Alkhouri N J Hepatol; 2021 Aug; 75(2):284-291. PubMed ID: 33746083 [TBL] [Abstract][Full Text] [Related]
48. Sex influences the association between appendicular skeletal muscle mass to visceral fat area ratio and non-alcoholic steatohepatitis in patients with biopsy-proven non-alcoholic fatty liver disease. Li G; Rios RS; Wang XX; Yu Y; Zheng KI; Huang OY; Tang LJ; Ma HL; Jin Y; Targher G; Byrne CD; Pan XY; Zheng MH Br J Nutr; 2022 Jun; 127(11):1613-1620. PubMed ID: 34176541 [TBL] [Abstract][Full Text] [Related]
49. The Presence of White Matter Lesions Is Associated With the Fibrosis Severity of Nonalcoholic Fatty Liver Disease. Petta S; Tuttolomondo A; Gagliardo C; Zafonte R; Brancatelli G; Cabibi D; Cammà C; Di Marco V; Galvano L; La Tona G; Licata A; Magliozzo F; Maida C; Marchesini G; Merlino G; Midiri M; Parrinello G; Torres D; Pinto A; Craxì A Medicine (Baltimore); 2016 Apr; 95(16):e3446. PubMed ID: 27100443 [TBL] [Abstract][Full Text] [Related]
50. Women Have a Lower Risk of Nonalcoholic Fatty Liver Disease but a Higher Risk of Progression vs Men: A Systematic Review and Meta-analysis. Balakrishnan M; Patel P; Dunn-Valadez S; Dao C; Khan V; Ali H; El-Serag L; Hernaez R; Sisson A; Thrift AP; Liu Y; El-Serag HB; Kanwal F Clin Gastroenterol Hepatol; 2021 Jan; 19(1):61-71.e15. PubMed ID: 32360810 [TBL] [Abstract][Full Text] [Related]
53. Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD. Hagström H; Nasr P; Ekstedt M; Hammar U; Stål P; Hultcrantz R; Kechagias S J Hepatol; 2017 Dec; 67(6):1265-1273. PubMed ID: 28803953 [TBL] [Abstract][Full Text] [Related]
54. Diagnostic value of MR-based texture analysis for the assessment of hepatic fibrosis in patients with nonalcoholic fatty liver disease (NAFLD). Cannella R; Borhani AA; Tublin M; Behari J; Furlan A Abdom Radiol (NY); 2019 May; 44(5):1816-1824. PubMed ID: 30788556 [TBL] [Abstract][Full Text] [Related]
55. Histopathological differences in patients with biopsy-proven non-alcoholic fatty liver disease with and without type 2 diabetes. Aller de la Fuente R; Mora Cuadrado N; Tafur C; López Gómez JJ; Gómez de la Cuesta S; García Sánchez MC; Antolin Melero B; de Luis Román DA Endocrinol Diabetes Nutr (Engl Ed); 2018; 65(6):354-360. PubMed ID: 29477355 [TBL] [Abstract][Full Text] [Related]
56. Ectodysplasin A Is Increased in Non-Alcoholic Fatty Liver Disease, But Is Not Associated With Type 2 Diabetes. Bayliss J; Ooi GJ; De Nardo W; Shah YJH; Montgomery MK; McLean C; Kemp W; Roberts SK; Brown WA; Burton PR; Watt MJ Front Endocrinol (Lausanne); 2021; 12():642432. PubMed ID: 33746906 [TBL] [Abstract][Full Text] [Related]
57. Association Between Fibrosis Stage and Outcomes of Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. Taylor RS; Taylor RJ; Bayliss S; Hagström H; Nasr P; Schattenberg JM; Ishigami M; Toyoda H; Wai-Sun Wong V; Peleg N; Shlomai A; Sebastiani G; Seko Y; Bhala N; Younossi ZM; Anstee QM; McPherson S; Newsome PN Gastroenterology; 2020 May; 158(6):1611-1625.e12. PubMed ID: 32027911 [TBL] [Abstract][Full Text] [Related]